Related Experiment Video
Updated: Jun 24, 2025
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
[Current status and future perspective of clinical trials for patients with multiple myeloma]
Tomotaka Suzuki1, Dai Maruyama2
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences.
Abstract:
There are two main types of clinical trials: industry-sponsored trials and investigator-initiated trials. Both of these, like the two sets of wheels on a car, are essential to development of treatments. Numerous clinical trials have been conducted in multiple myeloma, contributing to the development of new drugs and the current treatment landscape. Highly effective novel immunotherapies, such as bispecific antibodies and chimeric antigen receptor T-cell therapy, have emerged, and could be incorporated into the treatment landscape in the near future. However, given the improved performance of current standard therapies, the drawbacks (e.g., toxicity) of immunotherapy can be expected to outweigh the benefits (efficacy) in some patients. Therefore, clinical trials are designed to evaluate treatments stratified based on factors such as post-treatment efficacy and disease risk, and stratified treatment approaches are increasingly being considered as well as one-size-fits-all approaches to treatment development. In addition, the use of real-world data is being explored to make clinical trials more efficient. These approaches are expected to further improve the individualization and efficiency of multiple myeloma treatment.
Insights
Clinical trials are crucial for developing multiple myeloma treatments. Future trials will focus on personalized medicine and real-world data to improve treatment efficacy and efficiency.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Numerous clinical trials have advanced multiple myeloma treatment.
- Novel immunotherapies like bispecific antibodies and CAR T-cell therapy show promise.
- Current standard therapies are highly effective, necessitating careful evaluation of new treatments.
Purpose of the Study:
- To discuss the evolving landscape of clinical trials in multiple myeloma.
- To highlight the potential of immunotherapies and the need for stratified treatment approaches.
- To explore the integration of real-world data for enhanced trial efficiency.
Main Methods:
- Review of existing clinical trial methodologies in multiple myeloma.
- Analysis of emerging treatment modalities, including immunotherapies.
- Discussion of strategies for treatment stratification and the use of real-world data.
Main Results:
- Clinical trials have significantly shaped the current multiple myeloma treatment paradigm.
- Immunotherapies offer new avenues but require careful risk-benefit assessment.
- Stratified treatment approaches and real-world data utilization are key future directions.
Conclusions:
- Clinical trials remain essential for advancing multiple myeloma therapeutics.
- Personalized treatment strategies, informed by efficacy and risk, are increasingly important.
- Optimizing clinical trial design with real-world data will improve treatment individualization and efficiency.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...